C0013227||SQ(®) HDM SLIT-tablet
C0998367||house dust mite
C0155877||allergic asthma
C1556085||German
C0004096||Asthma
C0027361||people
C0013227||SQ(®) HDM SLIT-tablet
C0011318||Denmark
C0020517||allergy
C0021083||immunotherapy
C0013227||tablet
C0998367||house dust mite
C0155877||allergic asthma
C2607914||allergic rhinitis
C0023636||licensed
C0015176||Europe
C0013227||ACARIZAX plus
C0013216||pharmacotherapy
C0013227||placebo plus
C0013216||pharmacotherapy
C0998367||house dust mite
C0155877||allergic asthma
C0001617||inhaled corticosteroids
C1556085||German
C1457887||symptoms
C2607914||allergic rhinitis
C1535514||European
C0206035||phase III randomised controlled trial
C0013227||ACARIZAX
C0013227||placebo
C0087111||treatment
C1257890||groups
C0013216||pharmacotherapy
C0001617||inhaled corticosteroids
C2936789||short-acting β2-agonists
C0008976||trial
C0683525||treatment options
C0013227||ACARIZAX plus
C0013216||pharmacotherapy
C0013227||placebo plus
C0013216||pharmacotherapy
C0936012||analysis
C0936012||Deterministic sensitivity analyses
C0013227||ACARIZAX
C0087111||treatment
C0936012||analysis
C0013227||ACARIZAX plus
C0013216||pharmacotherapy
C0013227||placebo plus
C0013216||pharmacotherapy
C0998367||house dust mite
C0155877||allergic asthma
C0017480||Germany
C0936012||analysis
C0013227||ACARIZAX